-
Trying to leverage federal reimbursement cuts into support and resources for ICPs, the Association for Professionals in Infection Control and Epidemiology (APIC) has launched a series of educational initiatives in an ambitious follow-up to its ongoing efforts to eradicate methicillin-resistant Staphylococcus aureus (MRSA).
-
Frequent hand washing appears to heighten the risk for irritant contact dermatitis in health care workers, particularly those genetically predisposed to the condition, investigators report.
-
The perception of health care risks motivates behaviors in health care workers as well as patients. Several years after the SARS outbreak in China and Hong Kong, Japanese industrial scientists found that health care workers had a high perception of risk for SARS manifest primarily by a desire to avoid patients. At the same time these workers had a low acceptance of risk and felt little personal control.
-
In what could be a boon for infection surveillance and treatment programs, the Food and Drug Administration has approved a new rapid test for methicillin-resistant Staphylococcus aureus (MRSA) that can identify the bug in two hours.
-
Sign up now for AHC Media's upcoming audio conference, The Buck Stops Soon: Prevent CR-BSIs or Pay Up on Thursday, March 26, 2008, from 1 p.m-2:30 p.m. ET.
-
The Joint Commission has broadly expanded its emphasis on infection prevention in proposed 2009 patient safety goals that recommend specific strategies to fight a veritable "murderers' row" of health care-associated infections (HAIs).
-
What do you do when your successful hospital-based anticoagulation clinic has more patients than available slots? Detroit Medical Center pharmacist Candice Garwood, PharmD, faced that situation about three years ago and tells Drug Formulary Review she thought she had come up with a workable solutiontransition the most stable patients from the pharmacist-managed clinic to their physicians to continue their anticoagulation care.
-
Research at the University of Mississippi Medical Center indicating that statin therapy reduces risk of developing all cerebrovascular events (CVE) and ischemic stroke, but is associated with a nonsignificant increase in risk of hemorrhagic stroke, is not likely to cause a major change in medical practice.
-
FDA recently announced these approvals: Biogen Idec's Tysabri® (natalizumab) has been approved by FDA for treating moderate-to-severe Crohn's disease in patients with evidence of inflammation who have had an inadequate response to or are unable to tolerate conventional Crohn's disease therapies.
-
Electronic drug interaction alerts can be useful in preventing harmful drug-drug interactions, but too many clinically insignificant alerts can lead to "alert fatigue" and clinically significant alerts may be overridden.
